Postoperative Metabolic Phenoreversion in Clear Cell Renal Cell Carcinoma.
Malena ManziNicolás ZabaleguiMaría Eugenia MongePublished in: Journal of proteome research (2022)
The ultimate goal of surgical treatment in cancer is to remove the tumor mass for restoring a healthy state. A 16-lipid panel that discriminated healthy controls from clear cell renal cell carcinoma (ccRCC) patients in a prior study was evaluated in the present work in paired-serum samples collected from patients ( n = 41) before and after nephrectomy. Changes in the lipid and metabolite fingerprints from ccRCC patients were investigated and compared with fingerprints from healthy individuals obtained by means of ultra-performance liquid chromatography-high-resolution mass spectrometry. The lipid panel differentiated phenotypes associated with metabolic restoration after surgery, representing a serum signature of phenoreversion to a healthy metabolic state. In particular, PC 16:0/0:0, PC 18:2/18:2, and linoleic acid allowed discriminating serum samples from ccRCC patients with poor prognosis from those with an improved outcome during the follow-up period. Ratios of PC 16:0/0:0 and PC 18:2/18:2 with linoleic acid levels may contribute as prognostic tools to support decision-making during the patient follow-up care. The preliminary character of these results should be validated with larger cohorts, including subjects with different ethnicities, life style, and diets. MetaboLights study references: MTBLS1839, MTBLS3838, and MTBLS4629.
Keyphrases
- end stage renal disease
- poor prognosis
- ejection fraction
- liquid chromatography
- newly diagnosed
- chronic kidney disease
- high resolution mass spectrometry
- prognostic factors
- healthcare
- long non coding rna
- mass spectrometry
- fatty acid
- patients undergoing
- high resolution
- chronic pain
- case report
- young adults
- lymph node metastasis